Rinvoq
Rinvoq is a brand name for the drug Upadacitinib, which belongs to a class of medications known as Janus kinase (JAK) inhibitors. It works by blocking specific enzymes in the body that are involved in the immune response and inflammation process. Rinvoq is specifically approved for the treatment of moderate to severe active ulcerative colitis in adults who have not responded well to other medications. The recommended dosage of Rinvoq for ulcerative colitis is usually 15 mg once daily. The medication is available in tablet form and should be taken with or without food. Common side effects of Rinvoq include upper respiratory tract infections, headache, and nausea.
Kesimpta
Kesimpta is a brand name for the drug Ofatumumab, which belongs to a class of medications known as CD20-directed cytolytic monoclonal antibodies. It works by targeting and depleting certain B cells in the immune system, which play a role in inflammation and autoimmune conditions such as ulcerative colitis. Kesimpta is specifically approved for the treatment of relapsing forms of multiple sclerosis but has also shown promise in clinical trials for ulcerative colitis. The recommended dosage of Kesimpta for ulcerative colitis is 20 mg administered by subcutaneous injection once monthly. The medication is available in a prefilled syringe and should be administered under the supervision of a healthcare professional. Common side effects of Kesimpta include injection site reactions, upper respiratory tract infections, and headache.
Differences between Rinvoq and Kesimpta
The main difference between Rinvoq and Kesimpta lies in their mechanisms of action. Rinvoq is a JAK inhibitor that targets enzymes involved in the immune response and inflammation process, while Kesimpta is a CD20-directed cytolytic monoclonal antibody that depletes certain B cells in the immune system. Another difference is in their approved indications. Rinvoq is specifically approved for the treatment of moderate to severe active ulcerative colitis, while Kesimpta is primarily used for the treatment of relapsing forms of multiple sclerosis. The recommended dosages and administration methods also differ. Rinvoq is taken orally as a tablet once daily, whereas Kesimpta is administered as a subcutaneous injection once monthly. Additionally, Rinvoq and Kesimpta may have different side effects. While both medications can cause upper respiratory tract infections and headache, Rinvoq may also lead to nausea, while Kesimpta may cause injection site reactions. It is important to note that the choice between Rinvoq and Kesimpta for ulcerative colitis treatment should be made in consultation with a healthcare professional, taking into consideration the individual's specific condition and medical history.